Pharmaceutical News
2 articles on Pharmaceutical News, written by Shotlee and medically reviewed for clinical accuracy.
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
6 min read
Eli Lilly's Q1 Surge: GLP-1 Success Fuels Strong Outlook
Eli Lilly's first quarter of 2026 saw record-breaking performance, largely propelled by the immense demand for its GLP-1 based therapies, Mounjaro and Zepbound. The pharmaceutical giant not only surpassed financial expectations but also significantly raised its full-year outlook, signaling continued growth and innovation in the metabolic disease space.
7 min read